Varicella-zoster Virus Glycoprotein E
recombinant, E. coli
For in vitro use only!
Shipping: shipped on gel packs
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Purity: > 95 % (SDS-PAGE)
Form: liquid (Supplied in 60 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.25% Sarkosil, 10 mM Glutathione and 50% glycerol)
Antigen in ELISA and Western blots, excellent antigen for detection of VZV with minimal specificity problems.
The protein contains the VZV-gE immunodominant regions, amino acids 48-135. The protein is purified by proprietary chromatographic technique.
Background: Varicella-zoster virus (VZV) is an extremely cell-associated alpha herpesvirus. It interacts with cell surface heparan sulfate proteoglycans during virus attachment. VZV-gE is a glycoprotein that plays an active or supportive role in VZV cell membrane fusion. VZV-gE was found to enhance the fusogenic potential of VZV gB.
Specificity: Immunoreactive with sera of VZV-infected individuals.
BIOZ Product Citations:
Please click the arrow on the right to expand the citation list. Click publication title for the full text.
Maresova et al. (2005) Incorporation of three endocytosed varicellazoster virus glycoproteins, gE, gH, and gB, into the virion envelope. J. Virol. 79:997.
Taha et al. (2004) Are false negative direct immunfluorescence assays caused by varicella zoster virus gE mutant strains? J. Med. Virol. 73:631.
Pasieka et al. (2004) Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. J. Virol. 78:2884.
Mo et al. (2002) The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology. 304:176.
Kenyon et al. (2002) Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane. J. Virol. 76:10980.
Jaquet et al. (2002) Immunogenicity of a recombinant varicellazoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine. 20:1593.